Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt[®] technology to generate antibodies to a high-value target
Stockholm, Sweden - August 22, 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt[®] technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties. Under this collaboration agreement, Oblique will partner with Lilly Catalyze360-ExploR&D, a